ActualitésAssisté par IA

FDA Grants Breakthrough Status to GSK’s Jemperli

Jemperli gains FDA Breakthrough Designation for advanced rectal cancer after 100% cCR in clinical trials.

Par Priyanka Patil

Chargé(e) de marketing · Pharma Now

16 déc. 2024Updated Jun 26, 2025 · 2 min de lecture

Partager Ajouter comme source préférée

FDA Grants Breakthrough Status to GSK’s Jemperli — https://www.biospace.com/drug-development/gsk-to-approach-fda-with-positive-phase-iii-data-for-long-acting-asthma-med

Journalisme assisté par IA

Reviewed by Priyanka Patil, Chargé(e) de marketing · Pharma Now

GSK has announced that its immunotherapy, Jemperli (dostarlimab), has been granted Breakthrough Therapy Designation by the FDA for treating patients with locally advanced dMMR/MSI-H rectal cancer. This decision was supported by preliminary data from a trial showing an unprecedented 100% clinical complete response (cCR) in 42 patients. These promising results suggest potential to revolutionize the treatment approach for this cancer type.

Current standard treatment involves chemotherapy, radiation, and surgery, often resulting in significant long-term quality-of-life challenges. GSK's ongoing AZUR-1 trial aims to validate these groundbreaking findings.

SujetsActualités

Written by

Priyanka Patil

Chargé(e) de marketing · Pharma Now

Reporting on the science, business and regulation shaping the pharmaceutical industry.